JPWO2020076799A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020076799A5 JPWO2020076799A5 JP2021519595A JP2021519595A JPWO2020076799A5 JP WO2020076799 A5 JPWO2020076799 A5 JP WO2020076799A5 JP 2021519595 A JP2021519595 A JP 2021519595A JP 2021519595 A JP2021519595 A JP 2021519595A JP WO2020076799 A5 JPWO2020076799 A5 JP WO2020076799A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acids
- set forth
- sequence set
- linked amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 claims 68
- 239000000427 antigen Substances 0.000 claims 30
- 102000036639 antigens Human genes 0.000 claims 30
- 108091007433 antigens Proteins 0.000 claims 30
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 101150082854 Mertk gene Proteins 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 5
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 4
- 101100290803 Mus musculus Mertk gene Proteins 0.000 claims 4
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 4
- 238000013507 mapping Methods 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 101150022345 GAS6 gene Proteins 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 241000282567 Macaca fascicularis Species 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 238000004458 analytical method Methods 0.000 claims 3
- 230000003042 antagnostic effect Effects 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 229940127121 immunoconjugate Drugs 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000002818 protein evolution Methods 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 108010008177 Fd immunoglobulins Proteins 0.000 claims 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 2
- 108010043610 KIR Receptors Proteins 0.000 claims 2
- 102000002698 KIR Receptors Human genes 0.000 claims 2
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 claims 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 230000025194 apoptotic cell clearance Effects 0.000 claims 2
- 239000012830 cancer therapeutic Substances 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- 201000008443 lung non-squamous non-small cell carcinoma Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- 206010046885 vaginal cancer Diseases 0.000 claims 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 102000007471 Adenosine A2A receptor Human genes 0.000 claims 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 claims 1
- 101150051188 Adora2a gene Proteins 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 102100031487 Growth arrest-specific protein 6 Human genes 0.000 claims 1
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 201000005746 Pituitary adenoma Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102000052575 Proto-Oncogene Human genes 0.000 claims 1
- 108700020978 Proto-Oncogene Proteins 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022356 Tyrosine-protein kinase Mer Human genes 0.000 claims 1
- 101710103890 Tyrosine-protein kinase Mer Proteins 0.000 claims 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims 1
- 206010046392 Ureteric cancer Diseases 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046458 Urethral neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 238000000423 cell based assay Methods 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000019065 cervical carcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 108010004351 growth arrest-specific protein 6 Proteins 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- -1 small molecule compound Chemical class 0.000 claims 1
- 201000009295 smoldering myeloma Diseases 0.000 claims 1
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 210000004085 squamous epithelial cell Anatomy 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 230000005747 tumor angiogenesis Effects 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 201000011294 ureter cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862743507P | 2018-10-09 | 2018-10-09 | |
| US62/743,507 | 2018-10-09 | ||
| PCT/US2019/055155 WO2020076799A1 (en) | 2018-10-09 | 2019-10-08 | Anti-mertk antibodies for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512642A JP2022512642A (ja) | 2022-02-07 |
| JPWO2020076799A5 true JPWO2020076799A5 (enExample) | 2022-10-18 |
Family
ID=68345048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021519595A Pending JP2022512642A (ja) | 2018-10-09 | 2019-10-08 | がんを治療するための抗ＭｅｒＴＫ抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210395392A1 (enExample) |
| EP (1) | EP3864046A1 (enExample) |
| JP (1) | JP2022512642A (enExample) |
| KR (1) | KR20210072059A (enExample) |
| CN (1) | CN112839962A (enExample) |
| WO (1) | WO2020076799A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021020867A2 (pt) * | 2019-04-19 | 2022-01-04 | Genentech Inc | Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração |
| PH12022551398A1 (en) * | 2019-12-13 | 2023-10-09 | Alector Llc | Anti-mertk antibodies and methods of use thereof |
| JP2023519962A (ja) * | 2020-03-31 | 2023-05-15 | アレクトル エルエルシー | 抗ｍｅｒｔｋ抗体及びその使用方法 |
| EP4286406A4 (en) | 2021-01-29 | 2025-07-23 | Illimis Therapeutics Inc | FUSION MOLECULE WITH NON-INFLAMMATORY PHAGOCYTOSIS-INDUCING ACTIVITY |
| WO2022266223A1 (en) | 2021-06-16 | 2022-12-22 | Alector Llc | Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof |
| EP4355783A1 (en) | 2021-06-16 | 2024-04-24 | Alector LLC | Monovalent anti-mertk antibodies and methods of use thereof |
| JPWO2023063026A1 (enExample) * | 2021-10-15 | 2023-04-20 | ||
| CN116063507A (zh) * | 2022-05-11 | 2023-05-05 | 迈威(上海)生物科技股份有限公司 | 抗人gas6抗体或其抗原结合片段及其应用 |
| WO2024022495A1 (en) * | 2022-07-28 | 2024-02-01 | Concept To Medicine Biotech Co., Ltd. | Anti-MerTK ANTIBODIES AND USES THEREOF |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| CA2517145C (en) | 2003-03-05 | 2017-08-01 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| US20120230991A1 (en) * | 2008-07-29 | 2012-09-13 | Douglas Kim Graham | Methods and compounds for enhancing anti-cancer therapy |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| PL2699264T3 (pl) | 2011-04-20 | 2018-08-31 | Medimmune, Llc | Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1 |
| EP2785375B1 (en) | 2011-11-28 | 2020-07-22 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| CN104736168B (zh) | 2012-05-31 | 2018-09-21 | 索伦托治疗有限公司 | 与pd-l1结合的抗原结合蛋白 |
| DK2925350T3 (da) | 2012-12-03 | 2019-05-13 | Bristol Myers Squibb Co | Øgning af virksomheden mod cancer af immunomodulatoriske fc- fusionsproteiner |
| HRP20210122T1 (hr) | 2013-05-02 | 2021-04-16 | Anaptysbio, Inc. | Protutijela usmjerena protiv programirane smrti-1 (pd-1) |
| CN111423511B (zh) | 2013-05-31 | 2024-02-23 | 索伦托药业有限公司 | 与pd-1结合的抗原结合蛋白 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| ES2792183T3 (es) | 2013-09-13 | 2020-11-10 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
| PE20160953A1 (es) | 2013-12-12 | 2016-09-26 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| WO2016106221A1 (en) | 2014-12-22 | 2016-06-30 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
| CA2971734C (en) | 2014-12-22 | 2025-11-18 | Enumeral Biomedical Holdings Inc | Anti-pd-1 antibodies |
| MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
| EP3307777A4 (en) | 2015-06-11 | 2019-02-13 | Wuxi Biologics (Shanghai) Co. Ltd. | NOVEL ANTI-PD-L1 ANTIBODIES |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| FI3334763T3 (fi) | 2015-08-11 | 2024-10-30 | Wuxi Biologics Ireland Ltd | Uusia pd-l1-vasta-aineita |
| WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| HK1257840A1 (zh) | 2015-09-01 | 2019-11-01 | Agenus Inc. | 抗-pd-1抗体及其使用方法 |
| TW202208440A (zh) | 2015-12-14 | 2022-03-01 | 美商宏觀基因股份有限公司 | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 |
| EP3402512A4 (en) | 2016-01-11 | 2019-09-25 | Armo Biosciences, Inc. | INTERLEUKIN-10 IN THE PREPARATION OF ANTIGEN-SPECIFIC CD8 + T CELLS AND METHOD FOR THE USE THEREOF |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| EP3645041A4 (en) | 2017-06-28 | 2021-03-17 | The Rockefeller University | AGONISTIC ANTIBODY-ANTIBODY-ACTIVE INGREDIENT CONJUGATES AGAINST MERTK AND THEIR USES |
-
2019
- 2019-10-08 KR KR1020217013674A patent/KR20210072059A/ko not_active Withdrawn
- 2019-10-08 WO PCT/US2019/055155 patent/WO2020076799A1/en not_active Ceased
- 2019-10-08 CN CN201980067679.7A patent/CN112839962A/zh active Pending
- 2019-10-08 US US17/284,119 patent/US20210395392A1/en not_active Abandoned
- 2019-10-08 JP JP2021519595A patent/JP2022512642A/ja active Pending
- 2019-10-08 EP EP19794806.0A patent/EP3864046A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7171617B2 (ja) | 抗ＳＩＲＰα抗体 | |
| US12384853B2 (en) | Anti-HER2/PD1 bispecific antibody | |
| JPWO2021194942A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| JP2021531764A5 (enExample) | ||
| JP2019500891A5 (enExample) | ||
| AU2016306090A1 (en) | 5-bromo-2,6-di-(LH-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer | |
| RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
| AU2017260399A1 (en) | Humanized Anti-IL-1R3 antibodies | |
| KR20240145470A (ko) | 항-tigit 항체 및 항-pd-1/항-vegfa 이중특이적 항체를 포함하는 약제학적 조성물 및 용도 | |
| US20240101675A1 (en) | Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof | |
| JP2024054284A (ja) | ガンの処置のための結合分子 | |
| JPWO2020076799A5 (enExample) | ||
| WO2024119193A2 (en) | Mutant il-2 polypeptides and il-2 prodrugs | |
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| JP2023103352A5 (enExample) | ||
| JPWO2019195452A5 (enExample) | ||
| AU2019306113B2 (en) | Anti-human PD-L1 antibodies and their uses | |
| CN112074540A (zh) | 细胞接合的结合分子 | |
| WO2025016459A1 (zh) | 一种抗fgfr2/pd-1双特异性抗体 | |
| JPWO2020185722A5 (enExample) | ||
| IL321677A (en) | Anti-PDL1 antibodies, multispecific antibodies, and methods of use | |
| JP7745556B2 (ja) | Ｃｄ１３７結合分子及びその使用 | |
| JPWO2022212876A5 (enExample) | ||
| AU2023403270A1 (en) | Mutant il-2 polypeptides and il-2 prodrugs |